TABLE III.
Overall Survival Rates by Prognostic Variables for Grossly Resected Tumors Without Nodes
| Variables | No | 5 year OS (%) | RR of death | Log-rank test (P) |
|---|---|---|---|---|
| Total | 252 | 78 (73–83) | ||
| Age | ||||
| <3 | 72 | 86 (76–92) | 1 | NS |
| 3+ | 180 | 75 (69–81) | 1.51 | −0.17 |
| Site of the primary tumour | ||||
| Upper limb | 112 | 75 (66–82) | 1.34 | NS |
| Lower limb | 136 | 81 (74–87) | 1 | −0.25 |
| Site of the primary tumour | ||||
| Hand and foot | 43 | 64 (48–77) | 2.09 | 0.01 |
| Other | 205 | 82 (75–86) | 1 | |
| T status | ||||
| T1 | 203 | 82 (76–86) | 1 | 0.02 |
| T2 | 43 | 67 (52–79) | 1.92 | |
| Unknown | 6 | |||
| Tumor size | ||||
| <5 cm | 151 | 80 (72–85) | 1 | NS |
| >5 cm | 96 | 77 (67–84) | 1.29 | −0.32 |
| Unknown | 5 | |||
| Pathology | ||||
| Non alveolar | 90 | 83 (74–89) | 1 | NS |
| Alveolar | 162 | 76 (69–82) | 1.47 | −0.16 |
| Initial surgery | ||||
| Complete (IRS I) | 136 | 83 (76–88) | 1 | 0.05 |
| Micro residue (IRS II) | 116 | 73 (64–23) | 1.65 | |
| Chemotherapy | ||||
| VA | 36 | 86 (71–94) | 1 | NS |
| Alkyating agents (AA) | 103 | 85 (77–91) | 1.02 | −0.07 |
| AA + any anthracyclines | 94 | 70 (60–79) | 1.98 | |
| 6 drugs (CEVAIA) | 18 | 66 (43–84) | 2.04 | |
| Unknown | 1 | |||
| Chemotherapy duration | ||||
| < 23 weeks | 52 | 70 (56–81) | 2.39 | 0.004 |
| 24–26 weeks | 59 | 69 (56–79) | 2.39 | |
| >27 weeks | 141 | 85 (79–90) | 1 | |
| Initial radiation | ||||
| No | 104 | 79 (70–85) | 1 | NS |
| Yes | 129 | 77 (69–84) | 0.99 | |
| Unknown or amputation | 19 | |||
| Amputation | ||||
| No | 234 | 78 (72–83) | 0.86 | NS |
| Yes | 18 | 83 (59–94) | 1 | |
| Cooperative groups | ||||
| COG | 128 | 86 (79–90) | 1 | 0.004 |
| Europe | 124 | 70 (62–78) | 2.51 | |
| Era of treatment | NS | |||
| 1984–1994 | 171 | 76 (69–82) | 0.91 | −0.1 |
| 1995+ | 81 | 83 (74–90) | 1 |